Market potential

MULTIGUIDE REPRESENTS A SIGNIFICANT ADVANTAGE IN THE DEVELOPMENT OF NEW IMAGE GUIDED PROCEDURES

MultiGuide significantly lowers the cost and complexity associated with image guided interventions. As a result, MultiGuide may represent a shift from highly specialized procedures performed by few, to easy-to-perform procedures within the reach of any surgeon or physician. Additionally, it facilitates a shift from general to local anesthesia, increasing intervention accessibility.

These significant advantages open possibilities not yet seen for image guide procedures. The headache treatment may serve as an example of the market potential of one of several MultiGuide interventions.

Market potential

MIGRAINE & CLUSTER
HEADACHE TREATMENT

Treatment of migraine and cluster headache carry a large economic and societal impact. The annual cost associated with migraine is €55 billion in European Union alone. This represents a significant market potential for MultiGuide.

  • CHRONIC CLUSTER HEADACHE

    50 800 People suffering from chronic cluster headache in EU

    60% Estimated portion of this patient group that can be treated using MultiGuide

    76 200 Annual MultiGuide procedures, with each patient treated 2,5 times per year.

  • EPISODIC CLUSTER HEADACHE

    508 000 People suffering from episodic cluster headache in EU

    27% Estimated portion of this patient group that can be treated using MultiGuide

    342 900 Annual MultiGuide procedures, with each patient treated 2,5 times per year.

  • FREQUENT EPISODIC MIGRAINE

    14 224 000 People suffering from frequent episodic migraine in EU

    13% Estimated portion of this patient group that can be treated using MultiGuide

    9 243 600 Annual MultiGuide procedures, with each patient treated 2,5 times per year bilaterally.

  • CHRONIC MIGRAINE

    5 080 000 People suffering from chronic migraine in EU

    25% Estimated portion of this patient group that can be treated using MultiGuide

    6 350 000 Annual MultiGuide procedures, with each patient treated 2,5 times per year bilaterally.